Combination therapy using a dual PPAR-alpha/PPAR-gamma activator and a GLP-1 derivative for the treatment of metabolic syndrome and related diseases and disorders

摘要

The present invention relates to a pharmaceutical composition comprising a dual Peroxisome Proliferator-Activated Receptor-alpha/Peroxisome Proliferator-Activated Receptor-gama activator (PPAR-alpha/PPAR-gamma) and a Glucagon Like Peptide-1 (GLP-1) derivative for treating, preventing and reducing the risk of developing Type 2 diabetes, insulin resistance, dyslipidemia, obesity, hypertension and other related diseases and disorders.